Tapentadol
| Tapentadol | |
|---|---|
| Salts [] | |
|---|---|
| Tapentadol tartrate | |
| Tapentadol maleate | |
| Tapentadol phosphate | |
| Tapentadol hydrochloride | |
| Tapentadol hydrobromide | |
| Molecular structure drawn from PubChem coordinates |
| Physical properties [] | |
|---|---|
| Molecular mass | 221.34 g/mol [1] |
| Melting point | 202-205 [1] |
| Predicted LogP | 3.5 [1] |
| Structural Identifiers [] | |
|---|---|
| Molecular formula | C14H23NO |
| IUPAC name | 3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol |
| SMILES | CC[C@@H](C1=CC(=CC=C1)O)[C@@H](C)CN(C)C |
| InChI | InChI=1S/C14H23NO/c1-5-14(11(2)10-15(3)4)12-7-6-8-13(16)9-12/h6-9,11,14,16H,5,10H2,1-4H3/t11-,14+/m0/s1 |
| InChIKey | KWTWDQCKEHXFFR-SMDDNHRTSA-N |
| CAS number | 175591-23-8 |
| UNII | H8A007M585 |
| PubChem CID | 9838022 |
| Pharmacokinetics[] | |
|---|---|
| Onset | ~30 minutes |
| Elimination half-life | 4 hours |
| Duration of action | 4-6 hours |
| Metabolism | Hepatic (mostly via glucuronidation but also by CYP2C9, CYP2C19, CYP2D6) |
| Excretion | Urine and faeces (1%) |
| Routes of administration | By mouth |
| Dependence liability | High[3] |
| Addiction liability | High[4] |
| Toxicity [] | |
|---|---|
| LD50 | Rat: - iv: 40 mg/kg [1] |
Tapentadol (also known as Cg5503, Bn 200 (base), Cg5503 (base), Bn 200, Bn-200, Cg-5503, Cg5503 ir, 3-((1R,2R)-3-(Dimethylamino)-1-ethyl-2-methylpropyl)phenol, Cg 5503 or phenol, 3-[(1r,2r)-3-(dimethylamino)-1-ethyl-2-methylpropyl]-) is a substance of the phenylpropylamine class.
Chemistry
Salts []
Stereochemistry []
Tapentadol is a single defined stereoisomer (optical activity ( - )).
Druglikeness
Lipinski's rule of five
Tapentadol matches Lipinski's rule of five.Reagents
There are currently 5 reagent-interactions on DrugsPRO
| Reagent | Color change | Description |
|---|---|---|
| Marquis | magenta - reddish purple | |
| Mecke | light purple | |
| Mandelin | blue-gray (greenish) | |
| Liebermann | reddish brown | |
| Froehde | blue |
Pharmacology
ATC Classification
MeSH Classification
Mechanism of action []
Tapentadol is a centrally-acting synthetic analgesic. Although their clinical relevance is unclear, tapentadol is believed to have two main mechanisms of action. Tapentadol is a selective mu-opioid receptor (MOR) agonist: it binds to MOR with an affinity greater than or equal to ten-fold affinity compared to delta- and kappa-opioid receptors. Tapentadol also inhibits noradrenaline reuptake, thereby increasing noradrenaline levels and activating alpha-2 receptors to promote analgesia. Tapentadol is a weak serotonin reuptake inhibitor; however, this action does not contribute to its analgesic effect. [1]
Interactions []
Medical side effects []
119 side effects listed on drug labels in SIDER 4.1 (tapentadol).
- Nausea
- Dizziness
- Syncope
- Somnolence
- Constipation
- Vomiting
- Asthenia
- Fatigue
- Dry mouth
- Pruritus
- Insomnia
- Hyperhidrosis
- Anxiety
- Dyspepsia
- Irritability
- Lethargy
- Decreased appetite
- Pruritus generalised
- Menopausal symptoms
- Hot flush
- Vertigo
- Arthralgia
- Musculoskeletal discomfort
- Confusional state
- Feeling abnormal
- Depression
- Dyspnoea
- Dermatitis
- Rash
- Hypoaesthesia
- Hypotension
- Hypotensive
- Nasopharyngitis
- Nervousness
- Tension
- Tremor
- Upper respiratory tract infection
- Urinary tract infection
- Chills
- Drug withdrawal syndrome
- Abdominal discomfort
- Disturbance in attention
- Abnormal dreams
- Erectile dysfunction
- Vision blurred
- Feeling hot
- Anaphylactic shock
- Angioedema
- Mental disorder
- Diarrhoea
- Gastrointestinal disorder
- Hallucination
- Headache
- Cardiac disorder
- Immune system disorder
- Nervous system disorder
- Palpitations
- Panic attack
- Suicidal ideation
- Ataxia
- Breast disorder
- Infection
- Connective tissue disorder
- Cough
- Drug abuse
- Drug hypersensitivity
- Dysarthria
- Osteoarthritis
- Oedema
- Eye disorder
- Hypersensitivity
- Bundle branch block left
- Lung disorder
- Mediastinal disorder
- Nightmare
- Paraesthesia
- Convulsion
- Withdrawal syndrome
- Shock
- Loss of consciousness
- Tachycardia
- Pollakiuria
- Urethral disorder
- Urinary tract disorder
- Urticaria
- Angiopathy
- Weight decreased
- Agitation
- Depressed level of consciousness
- Gamma-glutamyltransferase increased
- Aspartate aminotransferase increased
- Alanine aminotransferase increased
- Urinary hesitation
- Malnutrition
- Skin disorder
- Disorientation
- Thinking abnormal
- Mental disability
- Illusion
- Memory impairment
- Respiratory depression
- Pulmonary function test decreased
- Muscle contractions involuntary
- Euphoric mood
- Bradycardia
- Coordination abnormal
- Impaired gastric emptying
- Feeling drunk
- Visual impairment
- Altered state of consciousness
- Sexual dysfunction
- Balance disorder
- Sensation of heaviness
- Drug interaction
- Serotonin syndrome
- Presyncope
- Oxygen saturation decreased
- Infestation
- Mental retardation
Indications
- Acute pain
- Chronic pain
- Diabetic peripheral neuropathy
- Low back pain
- Neuralgia
- Osteoarthritis
- Pain
- Postoperative pain
Subjective effects []
Experience reports
Erowid
There are currently 28 experience reports involving tapentadol on Erowid: []- "Through the Roof" by Luis A
- "Tramadol 2.0 Improved Version More Opioid-Like" by Pillster
- "Lucid Dreams" by SomeGuyFromTheWeb
- "Does What It's Suppose to Do" by Cynic
- "I Could Not Breathe!" by Moon Watch
- "This Is What I'm Talking About" by Man
- "Flying Monkey - AI Generated Cocktail" by Riffraff
- "Myoclonus?" by Cosmologist
- "Relapse and Binging" by Luis A.
- "Withdrawal" by an280
- "A 'Sticky' Kind of High" by J. Goodfellow
- "More Fun Than Expected" by oelcsm
- "Unique Effects Instantly" by Alchemist
- "Made All the Difference in the World" by ChemBob
- "Not to Be Underestimated" by Superheroine
- "Opiate Bliss" by numblover
- "Excellent Alternative" by rlawl
- "No Buzz but I Prefer It to Standard Opiates" by reenigne
- "I'm Here... But Not Here at All" by criminallygorgeous
- "My TwoCenta on Nucynta" by Bandit
- "After Two Weeks, I Discontinued" by sleepdust
- "Removed the Withdrawals and the Jonesing" by Critical386
- "Pleasant Silence" by whisperthesis
- "Worst Opioid Ever" by Jimmy Jane
- "NOT for the Nose" by YoungAndCareful
- "A Pleasant Surprise" by supersonic89
- "Loooove It" by ehh
- "Good for the Price" by GreenLikeAD's
Legal status []
- Australia: Tapentadol is a Schedule 8.
- Brazil: Tapentadol is a A1.[5]
- Canada: Tapentadol is a Schedule I.
- Germany: Tapentadol is a Anlage III under the "Betäubungsmittelgesetz (BtMG)".
- United Kingdom: Tapentadol is a Class A (Schedule 2 CD) under the "Misuse of Drugs Act 1971".
- United States: Tapentadol is a Schedule II under the "Controlled Substances Act".[6]
- European Union: Tapentadol is Prescription only.[7]
- United Nations: Tapentadol is Unscheduled.
- Other: Tapentadol is a SE: Förteckning II, In general: ℞ (Prescription only).[8]
See also []
External links []
References []
National Center for Biotechnology Information. PubChem Compound Summary for CID 9838022, Tapentadol. Accessed November 21, 2026. https://pubchem.ncbi.nlm.nih.gov/compound/9838022
U.S. Food and Drug Administration; National Center for Advancing Translational Sciences. Tapentadol. UNII: H8A007M585. Global Substance Registration System. Accessed November 21, 2026. https://gsrs.ncats.nih.gov/ginas/app/beta/substances/H8A007M585
Tapentadol (Monograph). American Society of Health-System Pharmacists (AHFS). 19 April 2023. https://www.drugs.com/monograph/tapentadol.html
Tapentadol Consumer Medicine Information. NPS MedicineWise. September 2020. https://www.nps.org.au/medicine-finder/palexia-ir-immediate-release-tablets
RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial. Diário Oficial da União. 2023-03-31. https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-784-de-31-de-marco-de-2023-474904992
Tapentadol. MedLine Plus. 2024-03-15. https://medlineplus.gov/druginfo/meds/a610006.html
Active substance(s): tapentadol. List of nationally authorised medicinal products. 21 July 2022. https://www.ema.europa.eu/documents/psusa/tapentadol-list-nationally-authorised-medicinal-products-psusa/00002849/202111_en.pdf
Palexia®, Filmdragerad tablett 50 mg. FASS.se. 3 November 2025. https://fass.se/health/product/20090507000010/fass-text
Data sources []
| Source | Status | Updated (UTC) |
|---|---|---|
| dosing | missing (no dosing statistics) | 2026-11-20 19:00:39 |
| drugspro | ok | 2026-11-20 19:00:35 |
| erowid | ok | 2026-11-20 19:00:37 |
| gsrs | ok | 2026-11-20 19:00:40 |
| hmdb | missing (no HMDB id) | 2026-11-20 19:00:35 |
| kegg | ok | 2026-11-20 19:00:37 |
| pubchem | ok | 2026-11-20 19:00:35 |
| ok | 2026-11-20 19:00:35 | |
| sider | ok | 2026-11-20 19:00:35 |
| structure | ok | 2026-11-20 19:00:35 |
| wikipedia | ok | 2026-11-20 19:00:36 |